Related by context. All words. (Click for frequent words.) 70 cannabinor 69 inhaled AAT 68 Phase 1a clinical 68 phase IIa 67 IIa trial 67 Phase IIA 67 OHR/AVR# 67 preclinical efficacy 67 bavituximab monotherapy trial 66 Quinamed 66 Squalamine 66 dose escalation Phase 66 GAMMAGARD 66 Phase IIIb clinical 66 pharmacokinetic PK study 66 tubulin inhibitor 66 Saforis 66 BrachySil TM 66 Phase IIb clinical trials 66 Phase IIa trials 66 initiate Phase 2b 65 YONDELIS 65 OncoGel 65 Phase Ib clinical 65 randomized Phase IIb 65 Tasimelteon 65 Phase IIB 65 NP2 Enkephalin 65 sitaxsentan 65 IIa clinical 65 ruxolitinib 65 Bayer HealthCare Onyx Pharmaceuticals 65 RhuDex 65 Phase #b/#a 65 initiate Phase IIa 65 IIa clinical trials 65 Phase Ib II 64 mertansine 64 Phase 2a clinical trials 64 multicenter Phase II 64 multicenter randomized placebo controlled 64 Phase Ib study 64 Zemplar Capsules 64 Phase Ia 64 Anavex #-# 64 phase IIb trial 64 Aplidin 64 Phase 1a 64 hepatitis B vaccine Heplisav 64 GLP toxicology studies 64 pain palliation 64 phase IIa clinical 64 generation purine nucleoside 64 Glypromate 64 Cimzia TM 64 EVIZON TM 64 relapsed MM 64 fosbretabulin 64 CRLX# 64 Deforolimus 64 AKT inhibitor 64 Multiple Ascending Dose 64 SEPET TM 64 Phase #b/#a trial 64 clevidipine 63 GALNS 63 lomitapide 63 Kahalalide F 63 novel oral anticoagulant 63 Archexin 63 SNT MC# 63 ONCONASE R 63 afamelanotide 63 Evoltra ® 63 Phase 1b trial 63 budesonide foam 63 Phase #b/#a clinical 63 HuMax EGFr 63 mTOR inhibition 63 VNP#M 63 alvespimycin 63 UPLYSO 63 LymphoStat B TM 63 PFO migraine 63 farletuzumab 63 phase IIb study 63 IMA# 63 Neo Bladder Augment 63 oral treprostinil 63 JAK inhibitor 63 orally dosed 63 phase IIb 63 OvaRex 63 candidates Dyloject TM 63 Neuvenge 63 Prodarsan 63 RSD# oral 63 preclinical pharmacokinetic 63 AZILECT ® 63 Plicera 63 antibody MAb 63 GENASIS 63 pharmacokinetic PK 63 thorough QT 63 hypoxia activated prodrug 63 Alferon N 63 vidofludimus 63 Temsirolimus 62 HQK 62 ularitide 62 Mipomersen 62 chronic thromboembolic pulmonary 62 INS# [001] 62 trastuzumab DM1 62 dosing cohort 62 INCB# [001] 62 MEND CABG II 62 R#/MEM # 62 receptor tyrosine kinase inhibitor 62 huN# DM1 62 Bruton tyrosine kinase Btk 62 trial evaluating PRX# 62 octreotide implant 62 Harry Palmin President 62 ZACTIMA 62 Factor VIIa 62 Orally administered 62 phase 2a 62 pharmacodynamic PD 62 MVA MUC1 IL2 62 MGd 62 Cloretazine 62 BCR ABL inhibitor 62 dose escalation clinical 62 phase Ib 62 Degarelix 62 neratinib 62 ganaxolone 62 Phase IIb III 62 Proellex TM 62 torezolid phosphate 62 Alzhemed TM 62 initiate Phase IIb 62 Cand5 62 lymphoid malignancies 62 PI3K/Akt pathway inhibitor 62 RE COVER 62 HDL Selective Delipidation 62 Catena ® 62 EGS# 62 Phase III multicenter 62 Fabry Disease 62 myeloproliferative diseases 62 phase IIb III 62 Initiate Clinical Trial 62 crizotinib PF # 62 DCVax R 62 TOLAMBA 62 pharmacokinetic PK profile 62 urocortin 2 62 Zybrestat 62 liposome formulation 62 biliary tract cancer 62 OvaRex ® MAb 62 Camvia 62 relapsed ALL 62 Lixivaptan 62 haematological cancers 62 AFRS TM 62 Trofex 62 JAK2 inhibitor 62 NeuVax 62 demonstrated antitumor activity 62 mGluR2 NAM 62 refractory prostate cancer 62 RezularTM 62 teriflunomide 62 trodusquemine 62 BIM #A# 62 PHX# 62 Safinamide 62 catheter occlusion 62 PANVAC VF 62 AQ4N 62 nucleotide analog 62 Zavesca r 62 Phase IIIb 61 recurrent glioma 61 Aryplase 61 TASKi3 61 IL# PE#QQR 61 Vidaza azacitidine 61 isoform selective 61 Azedra 61 DEEP AF 61 riociguat 61 Novolimus 61 PSMA ADC 61 rALLy clinical trial 61 fenretinide 61 Vitaxin 61 IPLEX 61 MAGE A3 ASCI 61 non nucleoside 61 Phase 1b 61 metastatic malignant 61 bortezomib Velcade 61 oral picoplatin 61 mg/m2 cohort 61 Tarceva TM 61 Phase III confirmatory 61 oral renin inhibitor 61 placebo controlled clinical 61 HGS# 61 Onconase 61 indibulin 61 oral prodrug 61 LAB CGRP 61 ACCLAIM II 61 HDACi 61 POSIDUR TM 61 EOquin TM 61 Rasagiline 61 Elagolix 61 phase Ib clinical 61 Alequel 61 Phase IIb trials 61 Phase Ib 61 Pimavanserin 61 Phase 2b clinical trials 61 DDP# 61 PPAR gamma agonist 61 ZOLINZA 61 Phase IIa trial 61 Phase IIIb study 61 ADAGIO study 61 PDE4 inhibitor 61 ORENCIA R 61 MYDICAR 61 trastuzumab DM1 T DM1 61 CVBT #H 61 bardoxolone 61 ATIR 61 GSK# [002] 61 Hepatocellular Carcinoma HCC 61 MGN# 61 omega interferon 61 selective S#P# receptor agonist 61 murine models 61 FOLOTYN ® 61 Laquinimod 61 clinical pharmacology studies 61 Prosaptide 61 humanized monoclonal 61 evaluating mipomersen 61 Canvaxin TM 61 optimal dosing regimens 61 SYN# 61 verteporfin 61 huC# DM4 61 abacavir Ziagen 61 IIb clinical trial 61 phase IIb clinical 61 forodesine 61 MEND CABG 61 phase IIIb 61 Phase 1b clinical 61 oxypurinol 61 BR.# 61 OvaRex R 61 TLK# 61 treatment naive genotype 61 thetreatment 61 KSP inhibitor 61 Altastaph 61 PSN# [002] 61 topically administered 61 Corlux 61 Phase 1b clinical trials 61 ESBA# 61 Virulizin ® 61 Talotrexin 61 SNT-MC#/idebenone 61 tolevamer 61 BLA filing 61 Cx# [002] 61 Omacetaxine 61 balsalazide tablet 61 IMC #B 61 Myelodysplastic Syndrome MDS 61 GRN# 61 Lucanix 61 epoetin alpha 61 malignant ascites 61 Aviptadil 61 multicenter clinical trials 61 Darusentan 61 BZL# 61 liposomal formulation 61 vivo preclinical 61 Tectin TM 61 Benlysta belimumab 61 histone deacetylase HDAC inhibitor 61 DUROS 61 Chronic myeloid leukemia 61 initiated Phase Ib 60 edifoligide E2F Decoy 60 Pivotal Phase III 60 vernakalant hydrochloride 60 RH1 60 Tykerb lapatinib 60 pivotal bioequivalence 60 Prodarsan ® 60 oral PTH 60 Xanafide 60 Tyrima 60 oral RSD# 60 midstage trials 60 hyperoxaluria 60 Xerecept 60 novel histone deacetylase 60 PROSTVAC ® 60 SUTENT ® 60 torezolid 60 Phase 2a clinical 60 Initiate Phase 60 recombinant factor VIIa 60 Trobalt 60 PD LID 60 pharmacodynamic effects 60 Fx #A 60 dexanabinol 60 Phase III 60 CCR9 antagonist 60 confirmatory clinical 60 PTH analogue 60 Cinquil 60 Monoclonal antibody 60 cardiac repolarization 60 CLORETAZINE TM VNP#M 60 rhIGF-I/rhIGFBP-3 60 pediatric pontine glioma 60 Genz # 60 CholeraGarde R 60 Dacogen decitabine 60 tramiprosate Alzhemed TM 60 CytoFabTM 60 Ozarelix 60 eculizumab therapy 60 Pivotal Clinical Trial 60 volociximab 60 Pazopanib 60 pediatric acute lymphoblastic 60 histone deacetylase inhibitor 60 DermaVir Patch 60 polycythemia vera PV 60 ATL# [001] 60 Civacir 60 Thorough QT 60 glucokinase activator 60 TransMID 60 IND submission 60 canakinumab 60 targeted antifolate 60 sargramostim 60 investigational humanized monoclonal antibody 60 Enkephalin 60 radiolabeled TM# 60 Avastin adjuvant 60 including eniluracil ADH 60 AGHD 60 bioequivalency 60 REGEN trial 60 Achieves Primary Endpoint 60 humanised monoclonal antibody 60 RELOVAIR ™ 60 antiangiogenic agent 60 Huntexil 60 Aflibercept 60 solithromycin 60 NOX E# 60 dose cohort 60 Afatinib 60 Hedgehog antagonist 60 Dextofisopam 60 Phase lll 60 Hsp# Inhibitor 60 synthetic retinoid 60 Denufosol 60 histamine dihydrochloride 60 Phase 2a trial 60 Stage IIB 60 Kepivance 60 Viprinex TM 60 enzastaurin 60 Solulin 60 AEG# 60 immuno therapeutic 60 registrational 60 Velcade bortezomib 60 initiate Phase 1b 60 nalbuphine ER 60 REG2 60 randomized multicenter trial 60 EndoTAG TM -1 60 Spiegelmer ® 60 antisense inhibitors 60 Cogane 60 HepDirect prodrug 60 recurrent herpes labialis 60 Granulocyte Colony Stimulating Factor 60 LidoPAIN SP 60 SAR# [004] 60 ulimorelin 60 Bendamustine 60 immatics 60 Urocidin 60 intranasal formulation 60 reslizumab 60 GED aPC 60 Initiates Clinical 60 NV1FGF 60 prospective multicenter study 60 dose escalation trial 60 ThGRF 60 multicentre randomized 60 polycythemia vera essential thrombocythemia 60 BRIM2 60 Exherin TM 60 PEARL SC 60 Poly ICLC 60 confirmatory Phase III 60 Telatinib 60 ospemifene 60 recurrent glioblastoma multiforme 60 Apoptone 60 Phase #/#a clinical 60 Dasatinib 60 Optiquel ™ 60 rotary VAD 60 TBC# 60 #I TM# 60 choroidal vasculopathy 60 CLL SLL 60 Fodosine 60 PrevOnco ™ 60 ARRY # 60 dextofisopam 60 concurrent chemoradiation 60 symptomatic paroxysmal AF 60 uricase 60 VitiGam 60 Panzem R NCD 60 p# inhibitor 60 immunomodulatory therapy 60 BrachySil ™ 60 Initiated Phase 60 eprotirome 60 VIBEX MTX 60 EP #R 60 PDE# inhibitors 60 preclinically 60 Phase II 60 paclitaxel poliglumex 60 AMD# [003] 60 non nucleoside HCV 60 PRT# 60 YONDELIS R 60 RE SURGE 60 randomized Phase 2b 60 Glybera 60 MEK inhibitor RDEA# 59 Phase IIIB IV 59 anticancer compound 59 multiple ascending dose 59 oral methylnaltrexone 59 teduglutide 59 GOUT 59 icatibant 59 nitric oxide donating prostaglandin 59 Certolizumab pegol 59 Pralatrexate 59 AeroLEF TM 59 HoFH 59 SUCCEED trial 59 Gleevec resistant 59 MELAS 59 thalidomide Thalomid 59 Pemetrexed 59 Almorexant 59 deforolimus 59 HCD# [002] 59 HIV HCV coinfected 59 gamma secretase inhibitor 59 pharmacokinetics PK 59 OVATURE 59 refractory metastatic colorectal cancer 59 Ventavis ® 59 CINTREDEKIN BESUDOTOX 59 Cloretazine ® 59 Actimmune ® 59 LEP ETU 59 eosinophilic asthma 59 ATPace TM 59 brivaracetam 59 Perceiva 59 Pivotal Trial 59 MyoCell SDF 1 59 HuMax CD4 59 NeuroVax 59 REMINYL ® 59 trastuzumab emtansine T DM1 59 acute mania 59 endothelin antagonist 59 rhFVIIa 59 Annamycin 59 IV Busulfex 59 CHAMPION PCI 59 Fibrillex 59 Onrigin 59 PENNVAX B 59 Ophena 59 VEGF inhibitor 59 RhuDex ® 59 Amplimexon 59 Traficet EN 59 orally bioavailable 59 epigenetic therapies 59 corticosteroid dexamethasone 59 Androxal TM 59 Feasibility Trial 59 immunotherapeutic vaccine 59 EVIZON 59 BRIM3 59 Allovectin 7 59 hyaluronidase enzyme 59 BRAF inhibitor 59 deferiprone 59 Valdoxan 59 ascending dose 59 Enzastaurin 59 Kamada AAT 59 ® natalizumab 59 Myocet 59 alemtuzumab Campath 59 TELINTRA 59 LBH# 59 Elocalcitol 59 Zarnestra 59 Litx 59 DCCR 59 kidney urologic 59 tezampanel NGX# 59 GW# [003] 59 lucinactant 59 topoisomerase II inhibitor 59 CBLC# 59 CoAxia 59 lenalidomide Revlimid 59 MDS AML 59 MYLOTARG 59 Soliris eculizumab 59 Solorel ® 59 II Clinical Trial 59 triphendiol 59 Symadex 59 DCVax Brain 59 rALLy 59 aerosolized KL4 surfactant 59 SERCA2a 59 autologous cellular immunotherapy 59 tiapamil 59 APTIVUS 59 AZILECT R 59 IMPACT DCM 59 ImmunoVEX HSV2 59 inhaled iloprost 59 QT QTc 59 lorvotuzumab mertansine 59 acyclovir Lauriad R 59 Insegia 59 HeFH 59 Removab 59 Plenaxis TM 59 Phase IIa proof 59 patientswith 59 monoclonal antibody conjugated 59 HDAC Inhibitor 59 Tracleer R 59 papillary renal cell carcinoma 59 Prodarsan R 59 lumiliximab 59 gefitinib Iressa 59 PRESEPT study 59 Phase 2b study 59 ABSORB trial 59 refractory anaplastic astrocytoma 59 DP b# 59 PREOS R 59 elotuzumab 59 candidate CRLX# 59 PRE SURGE 59 CRMD# 59 Phase #/#a 59 FTY# fingolimod 59 Phase III randomized controlled 59 Cinacalcet HCl 59 SAR# [002] 59 Phase III Clinical Trial 59 assessing T DM1 59 erythropoietic 59 Liprostin 59 lipopeptide 59 Anti VEGF 59 Sym# 59 Triapine 59 PrevOnco 59 Ampakine 59 TG# [003] 59 proliferative retinopathy 59 ToGA 59 Phase 2b trial 59 Vernakalant 59 Telintra 59 Alequel ™ 59 aurora kinase 59 retinal vein occlusion induced 59 PRTX 59 double blinded placebo 59 TACI Ig 59 inhibitor RG# 59 cilengitide 59 Phase 2a 59 dexpramipexole 59 MNTX 59 davunetide intranasal AL 59 Thrombin 59 Collategene 59 ANTEGREN 59 cediranib 59 NOD SCID mice 59 Alvesco R 59 Teysuno 59 sorafenib Nexavar 59 demonstrated clinically meaningful 59 vivo validation 59 multicenter Phase 59 p# biomarker 59 gemcitabine Gemzar ® 59 PEGylated interferon 59 Phase IIb clinical 59 BLA submission 59 PF # [002] 59 Pharmacokinetics PK 59 randomized controlled multicenter 59 Cloretazine R 59 QTinno TM 59 multicenter randomized controlled 59 Perforomist ™ Inhalation Solution 59 Memryte 59 oral deforolimus 59 PEG IFN 59 Ophena TM 59 Clolar ® 59 SPRYCEL ® 59 Vectibix panitumumab 59 Diamyd ® 59 elacytarabine 59 BAL# [002] 59 ritonavir boosting 59 DiaPep# 59 PET tracer 59 Zenvia Phase III 59 SIR Spheres 59 tarenflurbil 59 Personalized Immunotherapy 59 Tracleer r 59 basal insulin analogue 59 INSPIRE Trial Phase III 59 Dyloject TM 59 Muraglitazar 59 Lock Loop PLL 59 StemEx R 59 Technosphere ® 59 Aclidinium 59 BENLYSTA ® 59 Phase IIa clinical 59 Toraymyxin TM 59 Phase III Pivotal 59 SUVN 59 refractory ovarian cancer 58 Alequel TM 58 Vascugel ® 58 Cloretazine R VNP#M 58 ImmuKnow R 58 vivo potency 58 multikinase inhibitor 58 denileukin diftitox 58 Oglemilast 58 Arranon 58 R roscovitine 58 Rheos System 58 oral FTY# 58 renin inhibitor 58 Anturol TM 58 CLIRS 58 ENMD # 58 SYMMETRY trial 58 EndoTAG 58 MP4OX 58 STX# 58 PRECISE trial 58 XP #L 58 small molecule tyrosine 58 OncoVex 58 NanoEmulsion 58 bicifadine 58 investigational therapies 58 unoprostone isopropyl 58 peptide fragment 58 cytokine refractory 58 topical formulations 58 Diamyd R 58 DURIN TM 58 Tofacitinib 58 hPAM4 58 relapsing remitting MS RRMS 58 Golimumab 58 LUMINATE 58 Egrifta 58 idebenone 58 docetaxel Taxotere ® 58 midstage clinical 58 schizophrenia CIAS 58 desvenlafaxine succinate 58 selective modulator 58 Neurostep TM 58 LEVADEX ™ 58 Phase 2b monotherapy 58 single ascending dose 58 Urocortin 2 58 interferon beta 1b 58 EchoCRT 58 Nuvion 58 galiximab 58 Capesaris 58 DEB# 58 multicenter prospective 58 ZD# [001] 58 clinicaltrials 58 prucalopride 58 MIST II 58 Akt inhibitor 58 CA9 SCAN 58 LB# [003] 58 FVIIa 58 Angiotensin Converting Enzyme 58 PYY #-# 58 RhuDex TM 58 Cimzia ® certolizumab pegol 58 omacetaxine mepesuccinate 58 aplindore 58 BrachySil 58 EVIZON ™ 58 ThermoDox R 58 PS# DARA 58 ORENCIA ® 58 Pruvel 58 Hematologic 58 Sapacitabine 58 Pyridorin 58 VA# [002] 58 Mesafem 58 MEVACOR 58 Cleviprex TM clevidipine 58 receptor inhibitor 58 prospective randomized multicenter 58 rindopepimut 58 Virulizin R 58 E2F Decoy 58 Alocrest 58 velafermin 58 Xcellerated T Cells 58 ARIKACE ™ 58 edifoligide 58 sunitinib malate 58 PREVENT IV 58 Ocrelizumab 58 Triapine R 58 oral taxane 58 TRIST study 58 sJIA 58 albiglutide 58 buccal spray 58 Neulasta ® 58 Initiates Phase II 58 rituximab Rituxan 58 perifosine KRX 58 beta 1a 58 dasatinib Sprycel 58 MyVax personalized immunotherapy 58 Bioral Amphotericin B 58 incyclinide 58 CCR5 mAb 58 CDK inhibitor 58 DIABECELL 58 Dalbavancin 58 haematologic 58 TG MV 58 MVA BN 58 randomized multicentre 58 RhD positive 58 aerosolized surfactant 58 vascular disrupting agents 58 adult mesenchymal stem 58 Ketotransdel 58 somatostatin analogues 58 Bezielle 58 Iloperidone 58 Scopus Affiliation Identifier 58 AA Amyloidosis 58 dual endothelin receptor antagonist 58 Behcet uveitis 58 Blinatumomab 58 fidaxomicin Phase 3 58 smoldering myeloma 58 PKC# 58 OLYMPIA registry 58 CTAP# Capsules 58 Twinrix 58 wilate ® 58 Immunotherapeutic 58 E1 INT TM 58 cystinosis patients 58 Omnitarg 58 CardioFit 58 BNC# 58 Solorel 58 TMC# [002] 58 Aplidin R 58 PROCHYMAL 58 plasma kallikrein inhibitor 58 resolvin 58 pertuzumab 58 Phase 2b Clinical Trial 58 oral ridaforolimus 58 TEMSO 58 acute PAO 58 Surfaxin LS 58 Atu# 58 cortical stimulation therapy 58 MYCAMINE 58 recurrent glioblastoma 58 pediatric neuroblastoma 58 labial herpes 58 NP2 58 Enobia 58 OvaRex MAb 58 vaginally administered lidocaine 58 panitumumab Vectibix 58 Resolute stent 58 PresbyLens ® 58 pan HDAC inhibitor 58 Phase IIB clinical 58 Phase 2b Study 58 CCX# 58 Cethrin R 58 Roflumilast 58 Evoltra 58 samalizumab 58 recurrent malignant glioma 58 PTK# 58 axitinib 58 favorable pharmacokinetic profile 58 ELACYT 58 selective androgen receptor modulator 58 noninfectious uveitis 58 PEG SN# 58 Phase 2b kidney transplant 58 BiTE 58 florbetaben 58 5alpha reductase 58 GHRH 58 oral talactoferrin 58 CML CP 58 USL# 58 Abbokinase 58 Phase IIa 58 HuMax CD# 58 investigational monoclonal antibody 58 Lispro 58 CCR5 antagonist 58 intravitreal implant 58 masked placebo controlled 58 gallium nitrate 58 ACV1 58 NO# [002] 58 CAMPATH 58 proteasome inhibitor 58 leukemia AML 58 CRVO 58 VersaFilm 58 radiolabeled 58 Deferiprone 58 Targretin capsules 58 EDEMA3 58 Nascobal Nasal Spray 58 Vascugel 58 Fc fusion protein 58 Silodosin 58 Tocosol Paclitaxel 58 gastrointestinal stromal tumors GISTs 58 Darinaparsin 58 Lpathomab 58 multidose 58 vinca alkaloid 58 selective phosphodiesterase 58 anagrelide 58 purine analog 58 estramustine 58 Dacogen injection 58 PEGPH# 58 Ambrisentan 58 RNAi therapeutic targeting PCSK9 58 OncoVEX 58 PA# [002] 58 GLP1 agonist 58 tipifarnib 58 preclinical pharmacology 58 RE LY ® 58 CYT# potent vascular disrupting 58 RRMS patients 58 registrational trial 58 cortical stimulation 58 DSMB recommended 58 Vascular Disrupting Agent 58 KRN# 58 daily subcutaneous injections 58 G#DT 58 miglustat 58 TQT studies 58 Onalta ™ 58 DXL# 58 pioglitazone HCl 58 inhaled treprostinil 58 Sipuleucel T 58 chemo immunotherapy 58 cathepsin K inhibitor 58 immunological diseases 58 Antiangiogenic 58 vascular disrupting agent 58 randomized discontinuation 58 SPARLON 58 ORMD 58 aminotransferase 58 VIAject 58 luliconazole 58 VitiGam TM 58 Valtropin 58 phase III isavuconazole 58 Viramidine 58 Tesmilifene 58 ChronVac C R 58 BMAC System 58 iobenguane 58 pharmacodynamic profile 58 Glatiramer acetate 58 Lauriad 58 Panzem ® 57 Phase III HEAT 57 APEX PD 57 CUSTOM III 57 CARE HF 57 NDA Submission 57 PRIMO CABG 57 multicenter clinical 57 inhaled liposomal ciprofloxacin 57 Phase Ib IIa clinical 57 NEUVENGE 57 pomalidomide 57 lintuzumab 57 CVac 57 Pre RELAX AHF 57 migraine prophylaxis 57 Toremifene 57 EFAPROXYN 57 human microdosing 57 orBec 57 alefacept 57 baminercept 57 Alfimeprase 57 cardio renal 57 XL# SAR# 57 stated Michelle Berrey 57 Pertuzumab 57 Phase Ib IIa 57 radiolabelled 57 Pharmacokinetic studies 57 Myelodysplastic syndromes MDS